Price
5,013.5
-0.03%52W Range
Market Cap
₹59,943.91 Cr
Traded: ₹24.45 Cr (0.04%) 0.0x
Free Float: ₹3,320.89 Cr (0.74% of FF traded)
Volume · 60D trend
49.34 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | +13.0% | +8.0% | +12.0% | +0.0% | -- | Stable |
| ROE | +18.0% | +18.0% | +19.0% | -- | -- | Stable |
| Sales | +12.0% | +11.0% | +8.0% | -- | +13.0% | Stable |
| Profit | +12.0% | +9.0% | +32.0% | -- | +0.0% | Stable |
Quarterly Results
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,740 | 3,603 | 3,737 | 4,001 | 3,371 | 3,144 | 3,374 | 3,415 | 3,032 | 2,936 | 3,324 | 3,440 | 2,968 | 2,903 | 3,041 | 3,079 |
| Expenses | 2,974 | 3,086 | 2,909 | 3,080 | 2,632 | 2,752 | 2,615 | 2,662 | 2,423 | 2,534 | 2,616 | 2,693 | 2,579 | 2,549 | 2,442 | 2,625 |
| Operating Profit | 766 | 517 | 828 | 921 | 739 | 391 | 759 | 753 | 609 | 402 | 708 | 747 | 389 | 353 | 599 | 454 |
| Other Income | 153 | 65 | 90 | 104 | 149 | 146 | 93 | 134 | 120 | 76 | 42 | 6 | 66 | -34 | 45 | 51 |
| Interest | 47 | 54 | 42 | 35 | 30 | 28 | 36 | 28 | 29 | 27 | 25 | 30 | 30 | 29 | 27 | 25 |
| Depreciation | 100 | 106 | 95 | 94 | 88 | 112 | 85 | 79 | 80 | 83 | 70 | 74 | 72 | 78 | 78 | 77 |
| Profit Before Tax | 772 | 423 | 781 | 896 | 771 | 396 | 731 | 780 | 619 | 367 | 655 | 648 | 353 | 212 | 539 | 402 |
| Tax % | 32.0% | 40.0% | 16.0% | 13.0% | 13.0% | 18.0% | 12.0% | 10.0% | 11.0% | 17.0% | 8.0% | 5.0% | 18.0% | 68.0% | 15.0% | 14.0% |
| Net Profit | 521 | 251 | 653 | 779 | 668 | 322 | 641 | 702 | 550 | 304 | 604 | 615 | 288 | 68 | 460 | 348 |
| Exceptional Items | 0 | -135 | -53 | 0 | 13 | 0 | 0 | 0 | 0 | -13 | -51 | -58 | 0 | -103 | 0 | 0 |
| EPS (Rs) | 43.5 | 19.8 | 53.2 | 64.0 | 55.6 | 25.6 | 52.3 | 57.6 | 45.6 | 24.6 | 49.8 | 51.9 | 24.0 | 5.9 | 38.0 | 27.7 |
| Sales Growth (YoY) | 10.9% | 14.6% | 10.8% | 17.2% | 11.2% | 7.1% | 1.5% | -0.7% | 2.2% | 1.1% | 9.3% | 11.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 3.8% | -3.6% | -6.6% | 18.7% | 7.2% | -6.8% | -1.2% | 12.6% | 3.3% | -11.7% | -3.4% | 15.9% | 2.2% | -4.5% | -1.2% | -- |
| OP Growth (YoY) | 3.7% | 32.2% | 9.1% | 22.3% | 21.3% | -2.7% | 7.2% | 0.8% | 56.6% | 13.9% | 18.2% | 64.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | 48.2% | -37.6% | -10.1% | 24.6% | 89.0% | -48.5% | 0.8% | 23.6% | 51.5% | -43.2% | -5.2% | 92.0% | 10.2% | -41.1% | 31.9% | -- |
| Profit Growth (YoY) | -20.0% | 2.0% | 8.0% | 11.0% | 20.0% | 1.0% | -2.0% | 4.0% | 90.0% | 191.0% | 40.0% | 101.0% | 125.0% | -9.0% | -14.0% | -39.0% |
| EPS Growth (YoY) | -21.7% | -22.7% | 1.6% | 11.1% | 21.8% | 4.2% | 5.2% | 11.0% | 90.2% | 313.3% | 30.8% | 87.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 119.9% | -62.8% | -16.9% | 15.2% | 117.2% | -51.1% | -9.1% | 26.3% | 85.7% | -50.7% | -4.1% | 116.4% | 303.7% | -84.4% | 37.4% | -- |
| OP Margin | 20.5% | 14.3% | 22.2% | 23.0% | 21.9% | 12.4% | 22.5% | 22.1% | 20.1% | 13.7% | 21.3% | 21.7% | 13.1% | 12.2% | 19.7% | 14.8% |
| Net Margin | 13.9% | 7.0% | 17.5% | 19.5% | 19.8% | 10.2% | 19.0% | 20.6% | 18.1% | 10.3% | 18.2% | 17.9% | 9.7% | 2.3% | 15.1% | 11.3% |
| Material Cost % | 32.1% | 34.6% | 34.1% | 35.0% | 34.7% | 40.7% | 35.7% | 35.3% | 35.5% | 37.7% | 39.3% | 38.6% | 40.4% | 43.3% | 41.1% | 42.4% |
| Employee Cost % | 21.6% | 19.8% | 19.3% | 17.8% | 20.6% | 19.6% | 18.5% | 17.9% | 19.9% | 17.2% | 17.2% | 16.1% | 19.1% | 17.3% | 17.3% | 18.5% |
| P/S | 3.97 | 4.43 | 4.57 | 4.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 27.78 | 28.31 | 27.49 | 28.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.34 | 4.71 | 4.88 | 5.05 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of Part A of Schedule III thereto, we wish to inform you that ....
Please find attached herewith intimation for appointment of Mr. Laxmikant Tiwari and Mr. Nilesh Vartak as Senior Management Personnels of the Company.
Please find attached herewith intimation of Schedule of Analyst / Institutional Investor Meeting.
Please find attached herewith intimation for closure of trading window.
Please find attached herewith intimation for issue of corporate guarantee by the Company.
Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial - onset seizures in adult patients.
Please find attached herewith intimation for appointment of Dr. Shubhadeep Sinha as Senior Management Personnel of the Company.
Alkem Laboratories Limited launches Renocia ExoTM, India''s first patented Ginsenoside Exosome - based hair growth serum
Please find attached herewith Scrutinizer Report for 52nd Annual General Meeting of the Company.
Please find attached herewith Outcome of the 52nd Annual General Meeting of the Company and disclosure of voting results thereat.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Please find attached herewith Q1 FY27- Earnings Call Transcript.
Please find attached herewith Proceedings of the meeting of the equity shareholders of the Company and Scrutinizer''s Report on e-voting.
Please find attached herewith intimation for a copy of newspaper publication
With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q1FY27 Earnings Conference Call'' is available ....
The Financials Results of the Company for the quarter ended 30th June, 2026 having been communicated to the Stock Exchanges today ie 14th Aug the trading window shall open on 17th Aug, 2026.
Pl find attached herewith intimation under Reg 30
Pl find enclosed unaudited financial results along with LRR for quarter ended 30th June, 2026
Pl find enclosed press release and analyst presentation on Q1FY27 earnings and business updates of the Company
Please find enclosed herewith the outcome of Board meeting dated 14th Aug, 2026. The meeting of the Board of Directors of the Company commenced at 11 am and concluded at 13.40 pm. Kindly take the same
Please find attached herewith intimation about update on US FDA inspection at Company''s Manufacturing Facility Located at Amaliya, Daman.
Please find enclosed herewith the Notice of the 52nd Annual General Meeting of the Company scheduled to be held on Thursday, 27th August, 2026 at 11.00 a.m. through Video Conferencing (VC)/ ....
Please find attached herewith the Business Responsibility and Sustainability Report for the financial year ended 31st March, 2026.
Please find attached herewith the Notice of AGM alongwith the Annual Report for the FY 2025-2026.
Please find attached herewith intimation for Analyst / Investor Meet.
Please find attached herewith Intimation regarding Resignation of Senior Management Personnel.
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Please find attached herewith ....
Please Find Attached herewith intimation regarding update on Acquisition.
Please find attached herewith Newspaper Publication.
Please find attached herewith Disclosure under Regulation 30 of the SEBI LODR Regulations, 2015.
Notice convening the meeting of the equity shareholders of the Company
Please find attached herewith the copy of Newspaper Publication.
Please Find Attached herewith disclosure in respect of order passed by the Statutory Authority.
Please find attached herewith Copy of Newspaper Publication.
Please find attached herewith Analyst / Investor Meet - Intimation.
Please find attached herewith Analyst / Investor Meet - Intimation.
Please find enclosed herewith disclosure under Regulation 30 of SEBI LODR Regulations, 2015 - Updates on Acquisition
Please Find Attached herewith intimation regarding Closure of Trading Window.
Please find attached herewith Analyst / Investor Meet - Intimation.
Please find attached herewith Analyst / Investor Meet - Intimation.
Please Find Attached herewith Press Release.
Please find Attached herewith Q4 FY26- Earnings Call Transcript.
Please Find Attached Herewith the Annual Secretarial Compliance Certificate for the Financial Year ended 31.03.2026.
Attached please find herewith newspaper advertisement
Pl find enclosed herewith the outcome of the BM dated 28th May, 2026. The meeting of the Board of Directors of the Company commenced at 11.20 am and concluded at 13.15 pm.
The BOD at its meeting held today approved the reappointment of Mrs Madhurima Singh as Executive Director for a term of 5 consecutive years wef 20th Dec, 26.
Pl find enclosed Audited Financial Results along with auditors report for FY ended 31st march 26
Pl find enclosed press release and analyst presentation on Q4 and FY26 earnings and business updates of the Company.
The BOD at its meeting held today has recommended a final dividend of Rs. 10 per equity share of Rs. 2 each for FY ended 31st March 26 for approval of the shareholders of the Company at ....
Annual Reports
14Credit Ratings
6Concalls
49Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025Mar 2025
31 Mar 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Sep 2024
30 Sept 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Jun 2020
30 Jun 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Feb 2019
28 Feb 2019Oct 2018
31 Oct 2018Jul 2018
31 Jul 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Feb 2018
28 Feb 2018Nov 2017
30 Nov 2017Aug 2017
31 Aug 2017May 2017
31 May 2017Jan 2017
31 Jan 2017Nov 2016
30 Nov 2016Aug 2016
31 Aug 2016May 2016
31 May 2016Feb 2016
29 Feb 2016Held by ETFs
39 ETFs hold alkem · sorted by weight
Held by Mutual Funds
110 schemes hold alkem · sorted by weight